Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KB-0742 (Primary)
  • Indications Adenoid cystic carcinoma; Carcinoma; Chordoma; Diffuse large B cell lymphoma; Ewing's sarcoma; Liposarcoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Rhabdomyosarcoma; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Kronos Bio

    • Most Recent Events

    • 23 Jul 2024 According to a Kronos Bio media release, the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule.
    • 04 Jun 2024 Results ( As of January 4, 2024, n=112) assessing pdated KB-0742 safety, pharmacokinetics (PK), pharmacodynamic data (PD) and anti-tumor activity for patients from the ongoing dose escalation through 5 dose levels and 60 mg expansion, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 09 May 2024 According to a Kronos Bio media release, company presented posters of A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors at the American Association for Cancer Research (AACR) Annual Meeting in April 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top